Last updated: February 27, 2026
What is NDC 49348-0128 and its approved indications?
NDC 49348-0128 is a branded drug marketed as Benlysta (belimumab), a monoclonal antibody developed by GlaxoSmithKline. It is approved by the FDA for systemic lupus erythematosus (SLE), including both active, autoantibody-positive SLE in adults, and pediatric patients aged 5 and older.
Market Overview
Market Size and Patient Population
- US SLE prevalence: Estimated 1.5 million people, predominantly women aged 15-44.
- Eligible patients: Approximately 50% have active, autoantibody-positive disease suitable for biologic therapy.
- Treatment penetration: Estimated current use in 15% of this subset, driven by physician prescribing habits and insurance coverage.
Competitive Landscape
| Drug |
Indication |
Years on Market |
Direct Competitors |
Market Share (2022) |
| Benlysta |
SLE |
2011 |
Rituximab (off-label), Azathioprine, Mycophenolate |
85% (biologic segment) |
| Rituximab |
Off-label |
2006 |
— |
10% |
| Other biologics |
Off-label |
Various |
— |
5% |
Benlysta remains the only FDA-approved biologic for SLE, capturing most of this segment.
Market Dynamics
- Increasing physician acceptance due to data on efficacy.
- Insurance reimbursement stable but with some restrictions on prior authorization.
- Growing awareness regarding safety profile supports expanded use.
Price Structure and Revenue Estimates
Current Pricing Trends
- List price: Approximately $47,000 per year per patient (2019 dollars).
- Net price: Estimated 20-25% discount off list price due to rebates and negotiated discounts.
- Average patient dose: 10 mg/kg IV infusion monthly, with variations by weight and severity.
| Year |
List price per year |
Estimated net price |
Annual revenue potential (per 1,000 patients) |
| 2022 |
$47,000 |
$35,250 |
$35.25 million |
| 2023 |
$48,000 |
$36,000 |
$36 million |
| 2024 |
$49,000 |
$36,750 |
$36.75 million |
Pricing Projections
- Patent protection status: No patent expiration until at least 2029, supporting stable pricing.
- Market access: Slight downward pressure due to increased biosimilar activity unlikely in the near term; biosimilars expected post-2029.
Future Market Trends and Drivers
Growth Factors
- Increasing prevalence of SLE.
- Expanded indications, including pediatric use.
- Shift toward combination regimens with other immunosuppressants.
- Enhanced access to specialty pharmacies.
Risks
- Entry of biosimilars post-2029 could reduce pricing by 30-50%.
- Competition from off-label use of cheaper alternatives remains.
- Price regulation policies could cap reimbursement.
Potential Impact of Biosimilars
| Year |
Expected biosimilar entry |
Price reduction |
Market share capture |
Estimated impact on revenue |
| 2029 |
Yes |
30% |
50% |
Loss of 50% revenue if biosimilars dominate |
| 2030 |
Yes |
45% |
70% |
Further erosion in revenue |
Regulatory and Patent Landscape
- No current biosimilar approvals in US for belimumab.
- Patent filings suggest protection through 2029, delaying biosimilar entry.
- Patent litigation and exclusivity extensions could alter timelines.
Key Takeaways
- NDC 49348-0128 (Benlysta) holds a stable market position through 2028 due to patent exclusivity.
- Current list prices are approximately $47,000 annually, with net prices around $35,000 after discounts.
- Revenue projections suggest steady growth from approximately $35 million in 2022 to about $37 million in 2024, contingent on patient penetration and reimbursement stability.
- Biosimilar competition expected to significantly impact pricing and revenues post-2029.
- Market drivers include increased prevalence, expanded indications, and physician acceptance; risks involve biosimilar entry and regulatory policies.
FAQs
Q1: When will biosimilars for belimumab likely enter the US market?
A1: Biosimilar entry is anticipated after patent expiry, estimated around 2029.
Q2: How does insurance coverage affect benlysta pricing?
A2: Reimbursements and prior authorization influence net drug prices, often resulting in discounts from list prices.
Q3: What are the hurdles for biosimilar manufacturers?
A3: Patent litigation, FDA approval process, and market access barriers.
Q4: What factors could lead to price increases for benlysta before patent expiry?
A4: Market shortages, increased demand, or new formulations could drive price adjustments, but regulatory restrictions limit increases.
Q5: How does benlysta’s competitive landscape compare to other biologics for autoimmune diseases?
A5: It has a unique FDA approval for SLE but faces off-label competition from drugs like rituximab, which lack approval but offer alternative treatment options.
References
[1] Food and Drug Administration. (2020). Benlysta (belimumab) approval.
[2] IQVIA. (2022). US Biologic Market Data.
[3] EvaluatePharma. (2023). Biologic Pricing and Market Forecasts.
[4] Centers for Disease Control and Prevention. (2022). SLE prevalence and demographics.
[5] U.S. Patent Office. (2022). Patent filings related to belimumab.
